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as our strains were mostly resistant to penicillin, tetra- 
cycline, chloramphenicol and erythromycin, whereas, 
in Portugal, most of the 23F strains were not resistant 
to erythromycin [3]. 
There were many isolates of pneumococci with 
the same PFGE patterns in this study. Also, many of 
the 19F and 23F isolates showed the same pattern, 
which has only occasionally been encountered in other 
countries [8]. The horizontal spread of genetic material 
conveying resistance increments does not appear exten- 
sive, even though pneumococci are naturally trans- 
formable organisms [9]. Typically, members of the same 
clone should share a common serotype, antibiotic 
resistance profile and PFGE pattern. In this study, nine 
of 12 type 19F isolates with a C pattern and four of 
eight type 23F isolates with an L pattern showed the 
same multiresistance to penicillin, tetracycline, chloram- 
phenicol and erythromycin. Also, five of nine type 
23F isolates with a K pattern were multiresistant to 
penicillin, tetracycline and chloramphenicol. These 
results suggest that selection and spread of a few 
resistant clones has been the major cause of the high 
prevalence of penicillin-resistant strains. Another study 
in Korea showed that the resistance rate was only 
slightly lower for the isolates from outpatients [lo], 
whereas in other countries a much higher resistance 
rate has been reported in nosocomially acquired than 
in community-acquired infections [I 1,121. To verify 
our assumption, further study is required with the 
strains isolated from normal carriers or from com- 
munity-acquired infections. 
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Resistance of Sfrepfococcus pneumoniae to penicillin, 
erythromycin and third-generation cephalosporins in 
Seville, Southern Spain 
Clin Microbiol Infect 1997; 3: 382-385 
Resistance of Streptococcus pneumoniae to penicillin and 
third-generation cephalosporins is increasing in many 
countries, particularly in Spain, where some of the 
highest incidences of resistance to penicillin and other 
antimicrobial agents have been described [l]. Both 
penicillin-resistant (PRP) and -intermediate strains are 
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less susceptible to other p-lactams than penicillin- 
susceptible strains [2]. Third-generation cephalosporins 
have been considered to be an alternative for the 
treatment of infections caused by PRE? Nevertheless, 
strains resistant to third-generation cephalosporins have 
been described and, in sonie cases, therapeutic failures 
have been observed when these agents were used [3,4]. 
In this study, the activities of penicillin, cefotaxime, 
ceftriaxone, erythromycin and vanconiycin against 
clinical isolates of S. pneumoniae were determined. The 
incidence of resistance to these agents in our area and 
the relationship between resistance to third-generation 
cephalosporins and other agents were also evaluated. 
Two hundred and twelve S. pneumoniae strains, 
consecutively isolated from different patients between 
January 1993 and December 1995 at the University 
Hospital V. Macarena, Seville, Spain, were studied. The 
sources of the strains were sputum (84, 39.6%), blood 
culture (53, 25.0%), bronchial aspirate (23, 10.8%), 
ocular exudate (19, 9.0%), pleural effusion (9, 4.2%), 
cerebrospinal fluid (CSF) (4, 1.9%), and others (20, 
9.4%). Isolates were identified by standard methods [5]. 
S. pneumouiae ATCC 49619 arid Staphylococcus aureus 
ATCC 29213 were used as control strains. Penicillin 
G (Sigma, USA), cefotaxinie (Hoechst, Germany), 
ceftriaxone (Sigma, USA), erythroniycin (Sigma, USA) 
and vanconiycin (Lilly, USA) were used as standard 
powders of known potency. A microdilution assay 
using cation-adjusted Mueller-Hinton broth (Difco, 
USA), supplemented with 5% lysed horse blood (Difco, 
USA), was used, with incubation at  35°C for 24 h 
in air. The antimicrobial concentrations evaluated 
ranged froni 0.03 to 64 pg/mL. Strains were classified 
as susceptible, intermediate or resistant to penicillin 
when MIC values were 50.06, 0.125-1, or 22  pg/mL, 
respectively 161. Strains with MICs of cefotaxime or 
ceftriaxone of 1 pg/mL were considered intermediate, 
and those with MICs of 22  pg/mL resistant to these 
agents [ 71. Susceptibility categories for erythromycin 
and vanconiycin were established according to the 
NCCLS guidelines [6]. 
Range, MIC;,,, MICso values and percentages of 
intermediate and resistant strains to the antimicrobial 
agents evaluated are presented in Table 3 .  Considering 
penicillin G, 39.2% were intermtdiate and 12.3% were 
resistant, while 4.2% were resistmt to cefotaxinie and 
4.2% to ceftriaxone. Resistance to erythromycin was 
observed in 27.4% of the strains. N o  resistance to 
vancomycin was observed. 
The relationship between resistance to third- 
generation cephalosporins and penicillin resistance is 
shown in Table 2. All strains rrsistant to cefotaxinie 
and/or ceftriaxone (10, 4.7%) were also penicillin 
resistant. Resistant strains always had an MIC of third- 
generation cephalosporins of 2 pg/niL, except for 
one strain, for which the MIC of cefotaxinie was 
4 pg/mL. One strain was resistant to ceftriaxone 
(MIC 2 pg/mL) but susceptible to cefotaxime (MIC 
0.5 pg/mL). Another one was resistant to cefotaxinie 
(MIC 2 pg/niL) but susceptible to ceftriaxone (MIC 
0.5 pg/mL). Eighteen (8.4%) strains were interniediate 
to cefotaxime and 23 (9.8%) to ceftriaxone. All of 
them were also intermediate or resistant to penicillin. 
Of  penicillin-resistant and penicillin-intermediate 
strains, 57.7% and 43.496, respectively, were resistant to 
erythromycin. Similarly, 45.5% and 56.5% of cefo- 
taxinie-ceftriaxone-resistant and -intermediate strains, 
respectively, were resistant to erythromycin. 
Among the 57 strains isolated froni either blood or 
CSF, 18 (31.696) and eight (14%), respectively, were 
intermediate or resistant to penicillin G, and seven 
(12.3%) and two (3.5%), respectiv,:ly, were intermediate 
or resistant to third-generation cephalosporins. These 
values are similar to those obtained for the total strain 
population studied (see Table 1). 
There are many studies on  the resistance of S. 
pneurnoiziae to antimicrobial agents. The different results 
in those reports led to the recocimendation that each 
community should develop its own surveillance system 
to determine the local epideniicdogy of this problem. 
For this reason, we have studied the resistance of 
S. pneumoniae to five antimicrobial agents in our area, 
located in southern Spain. In this study, 12.3'%, of 
pneumococci were resistant to penicillin. In other areas 
of Spain, the current prevalence of PRP (MIC of 
penicillin > I  pg/niL) ranges from 10% to 2O'%,, 
depending on the age of the patients, the geographic 
area and the origin of the isolates [XI .  In other regions 
Table 1 Range, MICX and MlCso values (pg/niL) of five antinucrobial agents against S. pneumoniur (212 strains) 
Kansc MICx MICoii 94 lnterinediate 1% Ile\l\t.lncc 
l'cnicillin 50.03-4 0.125 2 39.2 12.3 
Cefotaximr 5 0. i 13 - 4 0.06 1 8.4 4.2 
Crftri~~xonc 50.03-2 0.06 1 9.8 4.2 
Erythroniycin 50.03->64 50.03 >63 4.2 27.4 
Vancornycin 50.03-1 0.2.5 0.25 0.0 0.0 
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Table 2 Relationship between susceptibility to penicillin 
and to cefotaxime-ccfiriaxone among 212 isolates of 
S. pneumoniae 
Cefotaxiuie Cefiriaxone 
Intermediate Resistant Intermediate Resistant 
(”/.I (“/.I (“w (“/.I 
Penicillin 
Susceptible 0.0 0.0 0.0 0.0 
Intermediate 4.2 0.0 5.6 0.0 
Resistant 4.2 4.2 4.2 4.2 
of Europe, the prevalence of PRP varies significantly 
from 0-5% (in Germany, Switzerland and Italy) to 
11 -1 7% (in France) to around 50% (in Hungary and 
Romania) [l]. Similar variations have been reported in 
the USA. In one large multicenter study, an overall 
incidence of 6.6% was reported [9], but the incidence 
was 61% in Kentucky among isolates from the naso- 
pharynx of children from day-care centers [lo]. 
The emergence of S. pneumoniae strains inter- 
mediate or resistant to third-generation cephalosporins 
has been recognized in several countries. Considering 
only resistant strains (MIC 22  pg/mL), data range from 
0% (Germany) to 2.5% (UK) to 4% (USA) [l]. Phrez- 
Trallero et a1 reported a prevalence of5.2% in northern 
Spain [ l l ] ,  a figure similar to that presented in this 
study (Table 1). The vast majority ofour S.  pneumoniae 
strains intermediate/resistant to third-generations 
cephalosporins were not susceptible to penicillin as has 
been previously reported. Resistance to cefotaxime and 
susceptibility to penicillin has also been described [12], 
but was not found among our strains. 
In Spain, Moreno et a1 reported an increasing 
resistance to erythromycin from 7.6% in 1988 to 15.2% 
in 1992, particularly in children under 5 years and 
hospitalized patients [13]. Similar trends have been 
observed in other European countries and the USA 
(14,151. In Barcelona (Spain), 13-2494 of S. pneumoniae 
isolates were resistant to erythromycin [8]. In our 
study, the resistance to this antimicrobial agent was 
even higher (27.4%). About one-quarter (25.8%) of 
erythromycin- resistant S. pneumoniae isolates were also 
resistant to penicillin, and 8.6% of them were also 
resistant to third-generation cephalosporins. As has 
been documented in all published reports, we found no 
strain resistant to vancomycin. 
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High-level aminoglycoside resistance and glycopeptide 
resistance among enterococci isolated from blood 
cultures, 1990-95 
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Recently enterococci have emerged as increasingly 
prominent pathogens in nosocomial infections [I]. The 
standard treatment for serious enterococcal infections is 
a bactericidal and synergistic combination of a p-lactam 
antibiotic (ampicillin or benzylpenicillin) or vanco- 
inycin with an aiiiinoglycoside [2]. Unfortunately, 
during the 1980s, high-level resistance (MIC> 2000 
nig/L) of enterococci to aniinoglycosides caused by 
aminoglycoside-modifying enzymes emerged rapidly, 
making the treatment of such infections difficult [3]. 
Since the late 1980s, glycopeptide-resistant enterococci 
have been reported in many parts of the world [4]. 
Most reports have described clusters of nosocomial 
infections 151. N o  established therapy exists for life- 
threatening diseases caused by such organisms. 
We previously reported the prevalence of high- 
level resistance to aiiiinoglycosides among enterococci 
isolated from blood cultures submitted to the Labora- 
torio di Microbiologia e Virologia of the Policlinico 
Careggi, Florence, Italy, from March 1990 to June 1991 
[6]. In that study, we found that 65.2% of Entevococcus 
.fac.calis strains were highly resistant to gentamicin, 
47.8% were highly streptoinicin resistant, and 86.9% 
were resistant to at least one of the aminoglycosides 
tested. We have continued monitoring this pheno- 
menon in Florence and we now report data on entero- 
coccal strains isolated from blood cultures updated to 
the end of 1995. From January 1995 we included the 
system (bioMkrieux, Marcy l'Etoile, France), which 
includes a screening test for highlevel aminoglycoside 
resistance, supplemented with 1:ests for motility and 
pigment production. The results are summarized in 
Table 1 .  The susceptibility card (GPS-TA) utilized from 
1990 to 1994 allowed detection of high-level resistance 
to gentanllcin (500 mg/L) and streptomycin (2000 
mg/L). Since January 1995, a different card (GPS-IR) 
has been used to determine the mtimicrobial suscepti- 
bility of enterococci. This card irtcludes a screening test 
for high-level gentamkin resistaiice only. A inicrotiter 
broth dilution method was utilized to detect strepto- 
mycin resistance and to confirm the resistance data 
obtained by the Vitek system. Broth microdilution 
minimum inhibitory concentrations (MICs) of vanco- 
mycin and teicoplanin were determined for strains that 
were shown to be glycopeptide resistant by the Vitek 
system. P-Lactamase production was tested with the 
chromogenic cephalosporin nitrocefin. 
In the last three years there has been a significant 
decrease in the prevalence of E. ,.faeralis highly resistant 
to gentamicin, in comparison with the three preceding 
years (chi"4.56; p<0.05). We did not find any 
particular explanation for this finding, and the low 
number of strains calls for caucion in formulating a 
hypothesis. Smaller variations were observed in strepto- 
mycin resistance. Twenty-three of 27 (85.2%) E. j&ralis 
strains with high-level resistance to gentanllciii isolated 
in the last three years were also highly resistant to 
streptomycin. No P-lactamase--producing strains of 
enterococci were found during the study period. 
In August 1994, a vancomytzin-resistant E. faeciuin 
strain (yielded in two blood cultures) was first isolated 
in Florence from a 46-year-old man with acute rnyeloid 
leukemia in the hematology unit of Careggi Hospital. 
In January 1995, a second vaiiconiycin-resistant E.  
faeciurn strain (yielded in three blood cultures) was 
recovered from a 74-year-old woman who had under- 
gone an operation for an aneurysm of the left carotid 
in the neurosurgery unit of the same hospital. Both 
isolates showed the Van A phenotype: MICs of vanco- 
mycin and teicoplaniii were 256 and 32 mg/L, and 256 
and 64 nig/L, respectively, for the two strains. Pulsed- 
field gel electrophoresis (PFGE)--based restriction frag- 
ment length polymorphism (1)NA RFLP) analysis 
